1997
DOI: 10.1590/s0037-86821997000400009
|View full text |Cite
|
Sign up to set email alerts
|

Zigomicose nasofacial no Estado do Pará: registro de dois casos

Abstract: São descritos dois casos de zigomicose nasofacial, procedentes de Belém, PA. O achado indica não ser tão rara, como se poderia supor, pela falta de registros, a ocorrência dessa micose na Região Norte do Brasil. Em ambos os pacientes, o tratamento pelo cetoconazol determinou involução rápida das manifestações clínicas, principalmente a obstrução nasal. Com o presente relato, sobe para cinco o número de casos da infecção referidos até agora do Estado do Pará.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
3
0
4

Year Published

2001
2001
2015
2015

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(8 citation statements)
references
References 1 publication
1
3
0
4
Order By: Relevance
“…Amphotericin B remains the only clinically effective antifungal drug even though its in vitro susceptibility data are usually more promising than clinical outcomes [1]. Our in vitro antifungal susceptibility testing showed a good activity of amphotericin B and was in agreement with our previous findings on the in vitro effect of azole antimycotics on A. corymbifera (Table 1) [6,7].Although Mucorales are generally considered as fungi primarily resistant to azole antimycotics, some in vitro susceptibility data and several reports have suggested that azole derivatives such as fluconazole [8][9][10][11][12][13], ketoconazole [14][15][16] and itraconazole [13,17,18] may be of some benefit in the treatment of mucormycosis, particularly caused by Absidia.There could be several causes of this controversy, such as the lack of an adequate antifungal susceptibility system for mucoraceous molds or the immunological status of host. Some of these case reports do not give the precise description of all predisposing factors and their changes in the course of the infection and thus some improvements or cures could result from the reconstruction of anti-infective mechanisms of host immunity.…”
Section: Disc Diffusion Test E (Inhibition Zone In Mm)supporting
confidence: 88%
“…Amphotericin B remains the only clinically effective antifungal drug even though its in vitro susceptibility data are usually more promising than clinical outcomes [1]. Our in vitro antifungal susceptibility testing showed a good activity of amphotericin B and was in agreement with our previous findings on the in vitro effect of azole antimycotics on A. corymbifera (Table 1) [6,7].Although Mucorales are generally considered as fungi primarily resistant to azole antimycotics, some in vitro susceptibility data and several reports have suggested that azole derivatives such as fluconazole [8][9][10][11][12][13], ketoconazole [14][15][16] and itraconazole [13,17,18] may be of some benefit in the treatment of mucormycosis, particularly caused by Absidia.There could be several causes of this controversy, such as the lack of an adequate antifungal susceptibility system for mucoraceous molds or the immunological status of host. Some of these case reports do not give the precise description of all predisposing factors and their changes in the course of the infection and thus some improvements or cures could result from the reconstruction of anti-infective mechanisms of host immunity.…”
Section: Disc Diffusion Test E (Inhibition Zone In Mm)supporting
confidence: 88%
“…Many antifungal drugs, such as potassium iodide, amphotericin B, imidazole derivatives (fluconazole, ketoconazole, and itraconazole), or a combination of two of these drugs, 2,4,[7][8][9][10][11][12]16 have been used for the treatment of rinoentomophthoramycoses. In the present case, a good response was obtained after surgery and subsequent treatment with potassium iodide.…”
Section: Discussionmentioning
confidence: 99%
“…1 Approximately 35 cases of rhinoentomophthoramycosis have been reported in Brazil. [2][3][4][5][6][7][8][9][10][11][12] The disease begins as a tumefaction of the mucosa of the inferior turbinate that spreads to other parts of the nasal cavity, paranasal sinuses, and subcutaneous tissue of the nose and surrounding areas. The infection initially appears as a nasal obstruction followed by diffuse erythema and thickening of the skin of the nose.…”
Section: Introductionmentioning
confidence: 99%
“…En pacientes diabéticos y en personas con inmunosupresión existe predisposición a la enfermedad, que se puede diseminar y ser fatal (21)(22)(23). En el manejo de la enfermedad se han empleado diversos agentes con resultados satisfactorios, entre ellos, yoduro de potasio, sulfas, ketoconazol, fluconazol e itraconazol (1,(9)(10)(11)(12)14,19,24).…”
Section: Discussionunclassified